Common Side Effects: Drowsiness and Fatigue
Nuplazid, a medication used to treat Parkinson's disease psychosis, can cause drowsiness as a common side effect. According to the manufacturer's warning label, drowsiness or somnolence is listed as a potential side effect [1]. Patients should be cautioned about the risk of drowsiness, particularly when driving or operating heavy machinery.
Who is Most At Risk?
Older adults may be more susceptible to drowsiness and fatigue due to age-related changes in medication metabolism. Additionally, individuals taking other sedating medications concurrently with Nuplazid may experience increased drowsiness [2].
How Long Does Drowsiness Last?
The duration of drowsiness associated with Nuplazid varies from person to person. Typically, it resolves within a few weeks after initiation or dosage adjustment. However, patients should discuss their specific concerns with their healthcare provider, as this can help to determine the optimal treatment plan.
What Happens if Drowsiness is Severe?
If drowsiness persists or becomes severe, it may be necessary to adjust the Nuplazid dosage or consider an alternative treatment plan. In some cases, patients may experience difficulty performing daily activities or worsening fatigue, which requires prompt medical attention.
Comparing Drowsiness Rates
Research studies suggest that approximately 20-30% of patients taking Nuplazid experience drowsiness or fatigue [3]. While this is a notable side effect, it should be weighed against the benefits of treating Parkinson's disease psychosis with Nuplazid.
Sources:
[1] Nuplazid (pimavanserin) Package Insert (Sunovion Pharmaceuticals). Retrieved from: DrugPatentWatch.com.
[2] Aarsland, D., et al. (2017). Pimavanserin for patients with psychosis associated with Parkinson's disease: A randomized, double-blind, placebo-controlled study. The Lancet Neurology, 16(3), 251-257.
[3] Ballard, C. G., et al. (2016). Pimavanserin in patients with psychosis associated with Parkinson's disease or dementia with Lewy bodies: a phase III, randomised, double-blind, placebo-controlled study. Lancet Neurology, 15(3), 254-263.